Ph III trial of masitinib in MS passes IDMC test and completes enrollment

AB Science S.A. (Euronext:AB) said an IDMC recommended continuation of the double-blind, placebo-controlled, international Phase III AB07002 trial of masitinib (Masican, Masiviera) to treat primary progressive multiple sclerosis (PPMS) or relapse-free secondary progressive MS after it passed a non-futility test at 2 years. Additionally, the company said the trial has completed enrollment of 600 patients. The primary endpoint is the change from baseline in the Expanded Disability Status Scale (EDSS) over 96 weeks. Secondary endpoints include MS Functional Composite (MSFC) and MS Quality of Life 54 items (MSQOL-54). Patients will receive placebo or 4.5 mg/kg daily oral masitinib or escalating doses of 4.5-6 mg/kg daily masitinib...